Literature DB >> 20153314

Effects of cannabinoid receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys.

Charles W Schindler1, Leigh V Panlilio, Joanne P Gilman, Zuzana Justinova, V Kiran Vemuri, Alex Makriyannis, Steven R Goldberg.   

Abstract

Cannabinoid receptor antagonists have shown some promise as treatments capable of reducing abuse and relapse to a number of abused drugs. In rodents, such effects have been observed with methamphetamine self-administration. However, the effects of cannabinoid receptor antagonists on methamphetamine self-administration and relapse have not been studied in primates. In the present study, rhesus monkeys were trained to respond on a three-component operant schedule. During the first 5-min component, fixed-ratio responses were reinforced by food, during the second 90- or 180-min component fixed-ratio responses were reinforced by i.v. methamphetamine. The third component was identical to the first. There was a 5-min timeout between each component. The effects of the cannabinoid receptor antagonists AM 251 and rimonabant were tested at various doses against self-administration of 3microg/kg/injection methamphetamine, and 1mg/kg AM 251 and 0.3mg/kg rimonabant were tested against the methamphetamine dose-effect function. The 1mg/kg dose of AM 251 was also tested for its ability to alter reinstatement of extinguished self-administration responding. The cannabinoid receptor antagonist AM 251 was found to reduce methamphetamine self-administration at doses that did not affect food-reinforced responding. The cannabinoid receptor antagonist rimonabant had similar, but less robust effects. AM 251 also prevented reinstatement of extinguished methamphetamine seeking that was induced by re-exposure to a combination of methamphetamine and methamphetamine-associated cues. These results indicate that cannabinoid receptor antagonists might have therapeutic effects for the treatment of methamphetamine dependence. Copyright 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20153314      PMCID: PMC2974174          DOI: 10.1016/j.ejphar.2010.02.005

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  28 in total

1.  Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine.

Authors:  Małgorzata Filip; Anna Gołda; Magdalena Zaniewska; Andrew C McCreary; Ewa Nowak; Wacław Kolasiewicz; Edmund Przegaliński
Journal:  Pharmacol Rep       Date:  2006 Nov-Dec       Impact factor: 3.024

2.  Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation.

Authors:  Amy J Tallett; John E Blundell; John R Rodgers
Journal:  Behav Pharmacol       Date:  2007-11       Impact factor: 2.293

3.  Endocannabinoid regulation of relapse mechanisms.

Authors:  Liana Fattore; Paola Fadda; Walter Fratta
Journal:  Pharmacol Res       Date:  2007-09-08       Impact factor: 7.658

4.  Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens.

Authors:  Zheng-Xiong Xi; Jeremy G Gilbert; Xiao-Qing Peng; Arlene C Pak; Xia Li; Eliot L Gardner
Journal:  J Neurosci       Date:  2006-08-16       Impact factor: 6.167

5.  Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys.

Authors:  Morten V Madsen; Linda Peacock; Thomas Werge; Maibritt B Andersen
Journal:  J Psychopharmacol       Date:  2006-03-13       Impact factor: 4.153

6.  Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats.

Authors:  Zheng-Xiong Xi; Krista Spiller; Arlene C Pak; Jeremy Gilbert; Christopher Dillon; Xia Li; Xiao-Qing Peng; Eliot L Gardner
Journal:  Neuropsychopharmacology       Date:  2007-08-29       Impact factor: 7.853

Review 7.  Modulation of the endocannabinoid system: therapeutic potential against cocaine dependence.

Authors:  Gianluigi Tanda
Journal:  Pharmacol Res       Date:  2007-09-11       Impact factor: 7.658

8.  The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding.

Authors:  Sherin Y Boctor; Joe L Martinez; Wouter Koek; Charles P France
Journal:  Eur J Pharmacol       Date:  2007-06-13       Impact factor: 4.432

9.  Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant.

Authors:  Zuzana Justinova; Patrik Munzar; Leigh V Panlilio; Sevil Yasar; Godfrey H Redhi; Gianluigi Tanda; Steven R Goldberg
Journal:  Neuropsychopharmacology       Date:  2008-02-27       Impact factor: 7.853

Review 10.  Endocannabinoid system involvement in brain reward processes related to drug abuse.

Authors:  Marcello Solinas; Sevil Yasar; Steven R Goldberg
Journal:  Pharmacol Res       Date:  2007-09-08       Impact factor: 7.658

View more
  13 in total

1.  Methamphetamine-induced dopamine terminal deficits in the nucleus accumbens are exacerbated by reward-associated cues and attenuated by CB1 receptor antagonism.

Authors:  Gabriel C Loewinger; Michael V Beckert; Hugo A Tejeda; Joseph F Cheer
Journal:  Neuropharmacology       Date:  2012-01-25       Impact factor: 5.250

Review 2.  Screening Medications for the Treatment of Cannabis Use Disorder.

Authors:  L V Panlilio; Z Justinova; J M Trigo; B Le Foll
Journal:  Int Rev Neurobiol       Date:  2016-03-10       Impact factor: 3.230

3.  The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators.

Authors:  Thomas F Gamage; Charlotte E Farquhar; Timothy W Lefever; Brian F Thomas; Thuy Nguyen; Yanan Zhang; Jenny L Wiley
Journal:  Neuropharmacology       Date:  2017-08-10       Impact factor: 5.250

Review 4.  Role of cues and contexts on drug-seeking behaviour.

Authors:  Christina J Perry; Isabel Zbukvic; Jee Hyun Kim; Andrew J Lawrence
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

5.  Comparison of the effects of methamphetamine, bupropion, and methylphenidate on the self-administration of methamphetamine by rhesus monkeys.

Authors:  Charles W Schindler; Joanne P Gilman; Leigh V Panlilio; David J McCann; Steven R Goldberg
Journal:  Exp Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.157

6.  Local pretreatment with the cannabinoid CB1 receptor antagonist AM251 attenuates methamphetamine intra-accumbens self-administration.

Authors:  Jesse S Rodriguez; Sherin Y Boctor; Luke C Flores; Clyde F Phelix; Joe L Martinez
Journal:  Neurosci Lett       Date:  2010-12-15       Impact factor: 3.046

Review 7.  Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

8.  Delayed emergence of methamphetamine's enhanced cardiovascular effects in nonhuman primates during protracted methamphetamine abstinence.

Authors:  D B Vaupel; C W Schindler; S Chefer; A M Belcher; I Ahmet; K B Scheidweiler; M A Huestis; E A Stein
Journal:  Drug Alcohol Depend       Date:  2015-12-24       Impact factor: 4.492

9.  Effects of the cannabinoid CB₁ receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats.

Authors:  Li Jing; Yanyan Qiu; Yanan Zhang; Jun-Xu Li
Journal:  Drug Alcohol Depend       Date:  2014-08-17       Impact factor: 4.492

10.  Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats.

Authors:  Xiang-Hu He; Chloe J Jordan; Kiran Vemuri; Guo-Hua Bi; Jia Zhan; Eliot L Gardner; Alexandros Makriyannis; Yan-Lin Wang; Zheng-Xiong Xi
Journal:  Acta Pharmacol Sin       Date:  2018-07-02       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.